Recent news about higher Treasury yields and rising oil prices has hurt many fast‑growing stocks, especially those tied to AI. Smaller companies, banks, and retailers also felt the pressure.
Because of that, I am looking for other parts of the market that could stay strong even if the current trend continues. One area that stands out is healthcare.
The healthcare sector is gaining momentum thanks to solid first‑quarter earnings, lower medical costs, and new Medicare Advantage payment rules. It is not fully bullish yet, but it is close to turning upward again.
The Center for Medicare & Medicaid Services recently announced a higher payment rate for 2027, adding $26 billion to the Medicare Advantage program. This extra cash helps insurers like UnitedHealth Group and gives a lift to the whole sector.
DaVita, a company that runs kidney‑dialysis clinics, also reported strong results. Its earnings beat expectations, the outlook for the year was raised, and it kept buying back its own shares. The stock is now close to its yearly high.
CMS also said it will cover popular GLP‑1 drugs such as Ozempic and Wegovy for eligible seniors at $50 a month. This move opens the market to many more patients.
Eli Lilly is the biggest winner from that decision. The company’s recent earnings beat estimates by almost $2 billion, and analysts raised their growth forecasts. The FDA also approved an oral GLP‑1 pill called Founday, which can be taken without food or water, expanding the drug’s reach.
While the broader healthcare sector looks hopeful, investors should also watch biotech stocks, which have been pulling back and could add extra risk.
In summary, strong earnings, better Medicare payments, and new drug approvals are all pointing to a possible bounce in healthcare stocks.
Source: Materials provided by https://articles.stockcharts.com.Note: Content may be edited for style and length.